GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Read More
Archive for In The News
In GSK’s Hoos, Scorpion Gains Oncology Pathfinder To Match Its $270m War Chest
Read More
GSK Oncology Exec Hoos Heads Back To Biotech As CEO Of Scorpion Therapeutics
Read More
Axel Hoos, The Keeper Of The Oncology Flame At Glaxosmithkline, Steps Away For His Next Challenge At Tiny Scorpion
Read More
J.P. Morgan 39th Annual Healthcare Conference
Read More
Scorpion Therapeutics Strikes Major $162m Funding Round For ‘Precision Oncology 2.0™’
Read More
With Biotech Funding At ‘All-time High,’ Scorpion Scoops Up $162 Million
Read More
Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0™ — We’ll Just Have To Wait For The Details
Read More
Scorpion Therapeutics Debuts With $108m To ‘put The Sting In Cancer’
Read More
Scorpion, Seeking To Develop ‘Precision Medicine’ Drugs For Cancer, Debuts With $108m In Funding
Read More